Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04209309 Completed - Clinical trials for Transcranial Magnetic Stimulation

Repetitive Transcranial Magnetic Stimulation as a Potential Tool to Reduce Sexual Arousal

Start date: October 1, 2014
Phase: N/A
Study type: Interventional

Hyper- and hyposexuality occur frequently in a variety of psychiatric disorders and are difficult to treat. While there is meta-analytic evidence for the significant effect of non-invasive brain stimulation on drug and food craving, no study has investigated the potential of this technique to modulate sexual behavior. The efficacy of a single session of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the left or right dorsolateral prefrontal cortex (DLPFC) to reduce sexual arousal was tested against a sham stimulation. To test this hypothesis, we employed a randomized, double-blind, sham-controlled crossover study design. Nineteen healthy male participants received high-frequency rTMS over the left DLPFC, high-frequency rTMS over the right DLPFC and sham rTMS (each 10 Hz; 110% resting motor threshold; 60 trains with 50 pulses) in randomized and counterbalanced order with a one-week interval between stimulation sessions to avoid carryover effects. Participants were exposed to neutral and sexual cues before and after each intervention and rated their sexual arousal after each block of cue presentation.

NCT ID: NCT04209101 Completed - Clinical trials for Psychoactive Substances Consumption

Medical Students and Psychoactive Substances Use

NC
Start date: January 1, 2017
Phase:
Study type: Observational

Medical students are heavy users of psychoactive substances, and even if levels of use vary depending on the universities, the average levels are higher than most other students. In France, however, the use of licit or illicit substance has not been precisely described in medical students. The aim of this study was therefore to define the different modes of consumption of medical students. Methods: This study was a cross-sectional survey in medical students from the University of Montpellier, and the investigators performed a cluster analysis of data. Both medical students and residents were included. Socio-demographic, medico-psychological and addictological data were collected.

NCT ID: NCT04208958 Completed - Colorectal Cancer Clinical Trials

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

ConsortiumIO
Start date: January 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer

NCT ID: NCT04208789 Completed - Clinical trials for Resistance to Tuberculostatic Drugs

Artificial Inteligent for Diagnosing Drug-Resistant Tuberculosis

Start date: June 15, 2020
Phase:
Study type: Observational

Title: Artificial Neural Network as Diagnostic Tools For Rifampicin-Resistant Tuberculosis In Indonesia. A Predictive Model Study and Economic Evaluation. Background: Drug-resistant tuberculosis has become a global threat particularly in Indonesia. The need to increase detection, followed by appropriate treatment is a concern in dealing with these cases. The rapid molecular test (specifically for detecting rifampicin-resistant) is now being utilized in health care service, particularly at primary care level with some challenges including the lack of quality control (including how to obtained and treat the specimen properly prior to the examination) which then, affect the reliability of the results. Drug-Susceptibility Test (DST) is still, the gold standard in diagnosing drug-resistant tuberculosis but this procedure is time-consuming and costly. The artificial intelligent including data exploration and modeling is a promising method to classify potential drug-resistant cases based on the association of several factors. Objective : 1. To develop a model using an artificial intelligence approach that is able to classify the possibility of rifampicin-resistant tuberculosis. 2. To assess the diagnostic ability and the accuracy of the model in comparison to existing rapid test and the gold standard 3. To evaluate the cost-effectiveness evaluation of Artificial Neural Network model in Web-Based Application in comparison with the standard diagnostic tools Methodology 1. A cross-sectional study involving all suspected drug-resistant tuberculosis cases that being referred to the study center to undergo rapid molecular test and DST test over the past 5 years. 2. A comprehensive, retrospective medical records assessment and tuberculosis individual report will be performed to obtain a variable of interest. 3. Questionnaire assessment for confirmation of insufficient information. 4. Model Building through machine learning and deep learning procedure 5. Model Validation and testing using training data set and data from the different study center Hypothesis : Artificial Intelligent Model will yield a similar or superior result of diagnostic ability compare the Rapid Molecular Test according to the Drug-Susceptibility Test. (Superiority Trial)

NCT ID: NCT04208464 Completed - Clinical trials for Idiopathic Inflammatory Myopathies

JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

MYOJAK
Start date: October 7, 2021
Phase: Phase 2
Study type: Interventional

This study aims to investigate the clinical efficacy of baricitinib in patients with adult idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will receive 24 weeks of baricitinib from the baseline visit with a 12 week follow-up period. The other half of patients will receive 24 weeks of barcitinib treatment after an initial 12-week delay with a 4 week follow up period for safety.

NCT ID: NCT04208139 Completed - Clinical trials for Recurrent Pulmonary Embolism (Disorder)

A Random Selection of Patients From the SENTRY Study Who Have a Bioconverted Sentry IVC Filter in Situ With a Minimum Dwell Time of 24 Months From a Single Center Follow up

Start date: March 14, 2020
Phase:
Study type: Observational

IVUS Evaluation of the Bioabsorbable Sentry IVC Filter 3-5 Years Post Deployment Follow up

NCT ID: NCT04207775 Completed - Clinical trials for Locally Advanced or Metastatic NSCLC

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

PISCES
Start date: March 30, 2020
Phase:
Study type: Observational

To estimate parameters associated with treatment patterns and related clinical outcomes.Including physician reported PFS and OS.

NCT ID: NCT04207697 Completed - Clinical trials for Rhinoconjunctivitis With or Without Allergic Asthma

Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Cat Dander

Start date: December 1, 2019
Phase:
Study type: Observational

Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerized With Cat Dander in allergic patients

NCT ID: NCT04207229 Completed - Hydrocephalus Clinical Trials

CERTAS Programmable Valve Registry

CERTAS
Start date: November 21, 2019
Phase:
Study type: Observational [Patient Registry]

Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.

NCT ID: NCT04207112 Completed - Clinical trials for Multi-drug Resistant Tuberculosis

Economic Evaluation of New MDR TB Regimens

PRACTECAL-EE
Start date: October 20, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The current treatment regimen for MDR-TB has poor outcomes and costs of treating MDR-TB are greater than treating drug susceptible TB, both in terms of health service and patient-incurred costs. Urgent action is needed to Identify short, effective and tolerable treatments for people with MDR-TB. The PRACTECAL economic evaluation sub-study (PRACTECAL-EE) will take place alongside the TB PRACTECAL trial, aiming to assess the costs to patients and providers of such regimens and to estimate the cost-effectiveness and poverty impact of an introduction of new MDR-TB regimens in the three countries participating in the main study.